The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer

BACKGROUND: Nowadays, patients with EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitive advanced non-small cell lung cancer (NSCLC) receive EGFR-TKIs as first-line treatment. We aimed to analyze the relationship between preliminary efficacy (tumor shrinkage within 1 month) and progression-free survi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ann Transl Med
Главные авторы: Chen, Dongfang, Chu, Tianqing, Chang, Qing, Zhang, Yanwei, Xiong, Liwen, Qiao, Rong, Teng, Jiajun, Han, Baohui, Zhong, Runbo
Формат: Artigo
Язык:Inglês
Опубликовано: AME Publishing Company 2019
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6545314/
https://ncbi.nlm.nih.gov/pubmed/31205913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.04.06
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы